Comprehensive Evaluation and Medical Management of Infrainguinal Peripheral Artery Disease: "When to Treat, When Not to Treat"

Techniques in Vascular and Interventional Radiology

Volumn 13, Issue 1, 2010, Pages 2-10

  Kiernan, Thomas J ^a   Hynes, Brian G ^a   Ruggiero, Nicholas J ^a   Yan, Bryan P ^a   Jaff, Michael R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

intermittent claudication; peripheral artery disease

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; NAFTIDROFURYL; PLACEBO;

ANKLE BRACHIAL INDEX; ARTERY DISEASE; ATHEROSCLEROSIS; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DIABETES MELLITUS; GLYCEMIC CONTROL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIMB ISCHEMIA; PHYSICAL EXAMINATION; REVIEW; RISK FACTOR; TOBACCO DEPENDENCE;

ALGORITHMS; ANGIOGRAPHY, DIGITAL SUBTRACTION; ARTERIAL OCCLUSIVE DISEASES; CLINICAL PROTOCOLS; CONSTRICTION, PATHOLOGIC; HUMANS; INTERMITTENT CLAUDICATION; ISCHEMIA; LOWER EXTREMITY; MAGNETIC RESONANCE ANGIOGRAPHY; PATIENT SELECTION; PERIPHERAL VASCULAR DISEASES; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 72249090066     PISSN: 10892516     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.tvir.2009.10.002     Document Type: Review

References (93)

1. Newman A.B., Shemanski L., Manolio T.A., et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol 19 (1999) 538-545
2. McDermott M.M., Mehta S., Ahn H., et al. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med 12 (1997) 209-215
3. Hirsch A.T., Criqui M.H., Treat-Jacobson D., et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286 (2001) 1317-1324
4. Hirsch A.T., Murphy T.P., Lovell M.B., et al. Gaps in public knowledge of peripheral arterial disease: The first national PAD public awareness survey. Circulation 116 (2007) 2086-2094
5. Hooi J.D., Kester A.D., Stoffers H.E., et al. Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: A longitudinal study. Am J Epidemiol 153 (2001) 666-672
6. Kannel W.B., and McGee D.L. Update on some epidemiologic features of intermittent claudication: The Framingham Study. J Am Geriatr Soc 33 (1985) 13-18
7. Dagenais G.R., Maurice S., Robitaille N.M., et al. Intermittent claudication in Quebec men from 1974-1986: The Quebec Cardiovascular Study. Clin Invest Med 14 (1991) 93-100
8. Hiatt W.R., Goldstone J., Smith Jr. S.C., et al. Atherosclerotic peripheral vascular disease symposium II: Nomenclature for vascular diseases. Circulation 118 (2008) 2826-2829
9. Rothwell P.M., Coull A.J., Silver L.E., et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 366 (2005) 1773-1783
10. Hooi J.D., Stoffers H.E., Knottnerus J.A., et al. The prognosis of non-critical limb ischaemia: A systematic review of population-based evidence. Br J Gen Pract 49 (1999) 49-55
11. Catalano M. Epidemiology of critical limb ischaemia: North Italian data. Eur J Med 2 (1993) 11-14
12. O'Hare A.M., Bertenthal D., Sidawy A.N., et al. Renal insufficiency and use of revascularization among a national cohort of men with advanced lower extremity peripheral arterial disease. Clin J Am Soc Nephrol 1 (2006) 297-304
13. Norgren L., Hiatt W.R., Dormandy J.A., et al. Inter-society consensus for the management of peripheral arterial disease. Int Angiol 26 (2007) 81-157
14. Bernstein E.F., and Fronek A. Current status of noninvasive tests in the diagnosis of peripheral arterial disease. Surg Clin North Am 62 (1982) 473-487
15. Ostergren J., Sleight P., Dagenais G., et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 25 (2004) 17-24
16. Resnick H.E., Lindsay R.S., McDermott M.M., et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: The Strong Heart Study. Circulation 109 (2004) 733-739
17. Fowkes F.G., Murray G.D., Butcher I., et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: A meta-analysis. JAMA 300 (2008) 197-208
18. American Diabetes Association: Peripheral arterial disease in people with diabetes. Diabetes Care 26 (2003) 3333-3341
19. Rutherford R.B., Lowenstein D.H., and Klein M.F. Combining segmental systolic pressures and plethysmography to diagnose arterial occlusive disease of the legs. Am J Surg 138 (1979) 211-218
20. Darling R.C., Raines J.K., Brener B.J., et al. Quantitative segmental pulse volume recorder: A clinical tool. Surgery 72 (1972) 873-877
21. Mallouhi A., Rieger M., Czermak B., et al. Volume-rendered multidetector CT angiography: Noninvasive follow-up of patients treated with renal artery stents. Am J Roentgenol 180 (2003) 233-239
22. Willmann J.K., Baumert B., Schertler T., et al. Aortoiliac and lower extremity arteries assessed with 16-detector row CT angiography: Prospective comparison with digital subtraction angiography. Radiology 236 (2005) 1083-1093
23. Wardlaw J.M., Chappell F.M., Best J.J., et al. Non-invasive imaging compared with intra-arterial angiography in the diagnosis of symptomatic carotid stenosis: A meta-analysis. Lancet 367 (2006) 1503-1512
24. Collins R., Burch J., Cranny G., et al. Duplex ultrasonography, magnetic resonance angiography, and computed tomography angiography for diagnosis and assessment of symptomatic, lower limb peripheral arterial disease: Systematic review. BMJ 334 (2007) 1257
25. Leiner T., Tordoir J.H., Kessels A.G., et al. Comparison of treatment plans for peripheral arterial disease made with multi-station contrast medium-enhanced magnetic resonance angiography and duplex ultrasound scanning. J Vasc Surg 37 (2003) 1255-1262
26. US Food and Drug Administration. CfDEaR, public health advisory: Gadolinium-containing contrast agents for magnetic resonance imaging (MRI): Omniscan, Optimark, Magnevist, prohance, and MultiHance. http://www.fda.gov/cder/drug/advisory/gadolinium_agents.htm Accessed September 8, 2006
27. Kock M.C., Adriaensen M.E., Pattynama P.M., et al. DSA versus multi-detector row CT angiography in peripheral arterial disease: Randomized controlled trial. Radiology 237 (2005) 727-737
28. Ockene I.S., and Miller N.H. Cigarette smoking, cardiovascular disease, and stroke: A statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. Circulation 96 (1997) 3243-3247
29. Price J.F., Mowbray P.I., Lee A.J., et al. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J 20 (1999) 344-353
30. Willigendael E.M., Teijink J.A., Bartelink M.L., et al. Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg 40 (2004) 1158-1165
31. Aboyans V., Criqui M.H., Denenberg J.O., et al. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation 113 (2006) 2623-2629
32. Juergens J.L., Barker N.W., and Hines Jr. E.A. Arteriosclerosis obliterans: Review of 520 cases with special reference to pathogenic and prognostic factors. Circulation 21 (1960) 188-195
33. Jonason T., and Bergstrom R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand 221 (1987) 253-260
34. Palumbo P.J., O'Fallon W.M., Osmundson P.J., et al. Progression of peripheral occlusive arterial disease in diabetes mellitus. What factors are predictive?. Arch Intern Med 151 (1991) 717-721
35. Sise M.J., Shackford S.R., Rowley W.R., et al. Claudication in young adults: A frequently delayed diagnosis. J Vasc Surg 10 (1989) 68-74
36. Valentine R.J., Jackson M.R., Modrall J.G., et al. The progressive nature of peripheral arterial disease in young adults: A prospective analysis of white men referred to a vascular surgery service. J Vasc Surg 30 (1999) 436-444
37. Girolami B., Bernardi E., Prins M.H., et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: A meta-analysis. Arch Intern Med 159 (1999) 337-345
38. Faulkner K.W., House A.K., and Castleden W.M. The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease. Med J Aust 1 (1983) 217-219
39. Burns P., Gough S., and Bradbury A.W. Management of peripheral arterial disease in primary care. BMJ USA 3 (2003) 277-281
40. A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service Report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. JAMA 283 (2000) 3244-3254
41. Bansal M.A., Cummings K.M., Hyland A., et al. Stop-smoking medications: Who uses them, who misuses them, and who is misinformed about them?. Nicotine Tob Res 6 suppl 3 (2004) 303-310
42. Annual smoking-attributable mortality, years of potential life lost, and economic costs-United States, 1995-99. Morb Mortal Wkly Rep 51 (2002) 300-303
43. Hurt R.D., Sachs D.P., Glover E.D., et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337 (1997) 1195-1202
44. Lancaster T., Stead L., Silagy C., et al. Effectiveness of interventions to help people stop smoking: Findings from the Cochrane Library. BMJ 321 (2000) 355-358
45. Roddy E. Bupropion and other non-nicotine pharmacotherapies. BMJ 328 (2004) 509-511
46. Safar M.E., and Frohlich E.D. The arterial system in hypertension. A prospective view. Hypertension 26 (1995) 10-14
47. Safar M.E., Levy B.I., and Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 107 (2003) 2864-2869
48. Kannel W.B., Skinner Jr. J.J., Schwartz M.J., et al. Intermittent claudication. Incidence in the Framingham Study. Circulation 41 (1970) 875-883
49. Safar M.E., Priollet P., Luizy F., et al. Peripheral arterial disease and isolated systolic hypertension: The ATTEST Study. J Hum Hypertens 23 (2009) 182-187
50. Calhoun D.A., Jones D., Textor S., et al. Resistant hypertension: Diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117 (2008) e510-e526
51. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the Joint National Committee on Prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 289 (2003) 2560-2572
52. Jamerson K., Weber M.A., Bakris G.L., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359 (2008) 2417-2428
53. Wing L.M., Reid C.M., Ryan P., et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348 (2003) 583-592
54. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
55. Smith Jr. S.C., Allen J., Blair S.N., et al. Guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation 113 (2006) 2363-2372
56. Feringa H.H., Karagiannis S.E., van Waning V.H., et al. The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease. J Vasc Surg 45 (2007) 936-943
57. McDermott M.M., Guralnik J.M., Greenland P., et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 107 (2003) 757-761
58. Mondillo S., Ballo P., Barbati R., et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 114 (2003) 359-364
59. Hirsch A.T., Haskal Z.J., Hertzer N.R., et al. Practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the Arab Cooperation Council/AHA, Task Force on Practice Guidelines, 2005 (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 113 (2006) e463-e654
60. Dawson D.L., Cutler B.S., Meissner M.H., et al. Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial. Circulation 98 (1998) 678-686
61. Money S.R., Herd J.A., Isaacsohn J.L., et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 27 (1998) 267-274 discussion 274-265
62. Regensteiner J.G., Steiner J.F., and Hiatt W.R. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg 23 (1996) 104-115
63. Leng G.C., Fowler B., and Ernst E. Exercise for intermittent claudication (Online). Cochrane Database Syst Rev (2000) CD000990
64. McDermott M.M., Ades P., Guralnik J.M., et al. Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: A randomized controlled trial. JAMA 301 (2009) 165-174
65. Gardner A.W., and Poehlman E.T. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA 274 (1995) 975-980
66. Zwierska I., Walker R.D., Choksy S.A., et al. Relative tolerance to upper- and lower-limb aerobic exercise in patients with peripheral arterial disease. Eur J Vasc Endovasc Surg 31 (2006) 157-163
67. Walters T.K., Mitchell D.C., and Wood R.F. Low-dose aspirin fails to inhibit increased platelet reactivity in patients with peripheral vascular disease. Br J Surg 80 (1993) 1266-1268
68. Cassar K., Bachoo P., Ford I., et al. Platelet activation is increased in peripheral arterial disease. J Vasc Surg 38 (2003) 99-103
69. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308 (1994) 81-106
70. Janzon L., Bergqvist D., Boberg J., et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 227 (1990) 301-308
71. Cacoub P.P., Bhatt D.L., Steg P.G., et al. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J 30 (2009) 192-201
72. Bhatt D.L., Flather M.D., Hacke W., et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 49 (2007) 1982-1988
73. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 (1996) 1329-1339
74. Skyler J.S., Bergenstal R., Bonow R.O., et al. Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 53 (2009) 298-304
75. Selvin E., Marinopoulos S., Berkenblit G., et al. Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141 (2004) 421-431
76. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
77. Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009) 129-139
78. Goto S. Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atherosclerosis Suppl 6 (2005) 3-11
79. Regensteiner J.G., Ware Jr. J.E., McCarthy W.J., et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: Meta-analysis of six randomized controlled trials. J Am Geriatr Soc 50 (2002) 1939-1946
80. Dawson D.L., Cutler B.S., Hiatt W.R., et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 109 (2000) 523-530
81. Beebe H.G., Dawson D.L., Cutler B.S., et al. A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial. Arch Intern Med 159 (1999) 2041-2050
82. Nony P., Boissel J.P., Lievre M., et al. Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis. Eur J Clin Pharmacol 46 (1994) 191-196
83. Samlaska C.P., and Winfield E.A. Pentoxifylline. J Am Acad Derm 30 (1994) 603-621
84. Hood S.C., Moher D., and Barber G.G. Management of intermittent claudication with pentoxifylline: Meta-analysis of randomized controlled trials. CMAJ 155 (1996) 1053-1059
85. Barradell L.B., and Brogden R.N. Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease. Drugs Aging 8 (1996) 299-322
86. De Backer T., Vander Stichele R., Lehert P., et al. Naftidrofuryl for intermittent claudication: Meta-analysis based on individual patient data. BMJ 338 (2009) b603
87. Lederman R.J., Mendelsohn F.O., Anderson R.D., et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): A randomised trial. Lancet 359 (2002) 2053-2058
88. Rajagopalan S., Mohler III E.R., Lederman R.J., et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: A phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108 (2003) 1933-1938
89. Kusumanto Y.H., van Weel V., Mulder N.H., et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: A double-blind randomized trial. Hum Gene Ther 17 (2006) 683-691
90. Creager MA, Olin JW, Belch J, et al: A randomized, double-blind, placebo-controlled, parallel group study of ad2/hypoxia inducible factor (HIF-1a/vp16) in patients with intermittent claudication. Paper presented at: The American College of Cardiology Annual Scientific Sessions; March 2009; Orlando, FL
91. Tateishi-Yuyama E., Matsubara H., Murohara T., et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: A pilot study and a randomised controlled trial. Lancet 360 (2002) 427-435
92. Linares-Palomino J.P., Gutierrez J., Lopez-Espada C., et al. Genomic, serologic, and clinical case-control study of Chlamydia pneumoniae and peripheral artery occlusive disease. J Vasc Surg 40 (2004) 359-366
93. Jaff M.R., Dale R.A., Creager M.A., et al. Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: Prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1). Circulation 119 (2009) 452-458